Beta Drugs Financial Statements
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
Y/e 31 Mar | Mar-2020 | - | - | - |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -- | -- | -- | -- |
Op profit growth | -- | -- | -- | -- |
EBIT growth | -- | -- | -- | -- |
Net profit growth | -- | -- | -- | -- |
Profitability ratios (%) | ||||
OPM | 19.70 | -- | -- | -- |
EBIT margin | 16 | -- | -- | -- |
Net profit margin | 10.40 | -- | -- | -- |
RoCE | -- | -- | -- | -- |
RoNW | -- | -- | -- | -- |
RoA | -- | -- | -- | -- |
Per share ratios () | ||||
EPS | 9.79 | -- | -- | -- |
Dividend per share | -- | -- | -- | -- |
Cash EPS | 5.88 | -- | -- | -- |
Book value per share | 59.40 | -- | -- | -- |
Valuation ratios | ||||
P/E | 4.09 | -- | -- | -- |
P/CEPS | 6.80 | -- | -- | -- |
P/B | 0.67 | -- | -- | -- |
EV/EBIDTA | 3.04 | -- | -- | -- |
Payout (%) | ||||
Dividend payout | -- | -- | -- | -- |
Tax payout | (21) | -- | -- | -- |
Liquidity ratios | ||||
Debtor days | -- | -- | -- | -- |
Inventory days | -- | -- | -- | -- |
Creditor days | -- | -- | -- | -- |
Leverage ratios | ||||
Interest coverage | (5.60) | -- | -- | -- |
Net debt / equity | 0.30 | -- | -- | -- |
Net debt / op. profit | 0.96 | -- | -- | -- |
Cost breakup () | ||||
Material costs | (49) | -- | -- | -- |
Employee costs | (10) | -- | -- | -- |
Other costs | (21) | -- | -- | -- |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
Y/e 31 Mar( In .Cr) | Mar-2020 | - | - | - |
---|---|---|---|---|
Revenue | 90.80 | -- | -- | -- |
yoy growth (%) | -- | -- | -- | -- |
Raw materials | (44) | -- | -- | -- |
As % of sales | 48.80 | -- | -- | -- |
Employee costs | (9.50) | -- | -- | -- |
As % of sales | 10.40 | -- | -- | -- |
Other costs | (19) | -- | -- | -- |
As % of sales | 21 | -- | -- | -- |
Operating profit | 17.90 | -- | -- | -- |
OPM | 19.70 | -- | -- | -- |
Depreciation | (3.80) | -- | -- | -- |
Interest expense | (2.60) | -- | -- | -- |
Other income | 0.41 | -- | -- | -- |
Profit before tax | 12 | -- | -- | -- |
Taxes | (2.60) | -- | -- | -- |
Tax rate | (21) | -- | -- | -- |
Minorities and other | -- | -- | -- | -- |
Adj. profit | 9.42 | -- | -- | -- |
Exceptional items | -- | -- | -- | -- |
Net profit | 9.42 | -- | -- | -- |
yoy growth (%) | -- | -- | -- | -- |
NPM | 10.40 | -- | -- | -- |
- Switch to
-
Tabular DataGraph
Y/e 31 Mar ( In .Cr) | Mar-2020 | - | - | - |
---|---|---|---|---|
Profit before tax | 12 | -- | -- | -- |
Depreciation | (3.80) | -- | -- | -- |
Tax paid | (2.60) | -- | -- | -- |
Working capital | -- | -- | -- | -- |
Other operating items | -- | -- | -- | -- |
Operating cashflow | -- | -- | -- | -- |
Capital expenditure | -- | -- | -- | -- |
Free cash flow | -- | -- | -- | -- |
Equity raised | -- | -- | -- | -- |
Investments | -- | -- | -- | -- |
Debt financing/disposal | -- | -- | -- | -- |
Dividends paid | -- | -- | -- | -- |
Other items | -- | -- | -- | -- |
Net in cash | -- | -- | -- | -- |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
Y/e 31 Mar ( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | - |
---|---|---|---|---|
Equity capital | 9.61 | 8.65 | 8.65 | -- |
Preference capital | -- | -- | -- | -- |
Reserves | 47.50 | 32.30 | 24.20 | -- |
Net worth | 57.10 | 40.90 | 32.90 | -- |
Minority interest | ||||
Debt | 22.60 | 20 | 7.50 | -- |
Deferred tax liabilities (net) | 0.23 | 0.15 | 0.15 | -- |
Total liabilities | 79.90 | 61 | 40.50 | -- |
Fixed assets | 43.90 | 32.40 | 14.50 | -- |
Intangible assets | ||||
Investments | 0.35 | 0.35 | -- | -- |
Deferred tax asset (net) | 0.40 | 0.29 | -- | -- |
Net working capital | 29.90 | 24.70 | 14.10 | -- |
Inventories | 12.40 | 9.53 | 2.80 | -- |
Inventory Days | 49.60 | -- | -- | -- |
Sundry debtors | 31.90 | 25 | 14.40 | -- |
Debtor days | 128 | -- | -- | -- |
Other current assets | 13.10 | 11.80 | 5.89 | -- |
Sundry creditors | (16) | (16) | (6.10) | -- |
Creditor days | 65.70 | -- | -- | -- |
Other current liabilities | (11) | (6.10) | (3) | -- |
Cash | 5.39 | 3.30 | 11.90 | -- |
Total assets | 79.90 | 61 | 40.50 | -- |
- Switch to
-
ConsolidatedStandalone
Beta Drugs Ltd Report not showing data |
---|